Short Interest Moves 19% Higher For PGNX Thursday, April 25, 4:25 PM ET, by Market News Video Staff The most recent short interest data has been released by the NASDAQ for the 04/15/2013 ...
First Week of PGNX August 2014 Options Trading Friday, December 27, 11:13 AM ET, by Market News Video Staff Investors in Progenics Pharmaceuticals, Inc. (PGNX) saw new options begin trading this week, for the ...
Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock, but tentative about paying the going market price of $4.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $4 strike, which has a bid at the time of this writing of 50 cents. Collecting that bid as the premium represents a 12.5% return against the $4 commitment, or a 29.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to PGNX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $4 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Progenics Pharmaceuticals, Inc. sees its shares decline 16.3% and the contract is exercised (resulting in a cost basis of $3.50 per share before broker commissions, subtracting the 50 cents from $4), the only upside to the put seller is from collecting that premium for the 29.1% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Progenics Pharmaceuticals, Inc., and highlighting in green where the $4 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the November put at the $4 strike for the 29.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Progenics Pharmaceuticals, Inc. (considering the last 249 trading day closing values as well as today's price of $4.70) to be 108%. For other put options contract ideas at the various different available expirations, visit the PGNX Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Wednesday, the put volume among S&P 500 components was 1.26M contracts, with call volume at 1.62M, for a put:call ratio of 0.78 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers.
This Article's Word Cloud:DefinitionNovemberOptionsPGNXPharmaceuticalsProgenicsStockYieldBoostamongannualizedbenefitbuyerscallcomparedcontractexercisedfromgoinghistorymarketmonthonlyoptionsotherowningpremiumpricerateratiorepresentsreturnsellersellingsharesharesstockstrikethattherethistodaytradingtrailingtwelveupsidevolatilitywherewhichwithwould
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
Play Video:
How To Sell A PUT
Start slideshow: